Estimands: discussion points from the PSI estimands and sensitivity expert group

Pharmaceutical Statistics

Volumn 16, Issue 1, 2017, Pages 6-11

  Phillips, Alan ^a   Abellan Andres, Juan ^b   Soren, Andersen ^c   Bretz, Frank ^d   Fletcher, Chrissie ^e   France, Lesley ^f   Garrett, Andrew ^g   Harris, Raymond ^h   Kjaer, Magnus ^f   Keene, Oliver ⁱ   Morgan, David ^j,m   O'Kelly, Michael ^g   Roger, James ^k,l  

^a ICON PLC   (United Kingdom)

^b GRÜNENTHAL GMBH   (Germany)

^c NOVO NORDISK A S   (Denmark)

^d NOVARTIS PHARMA AG   (Switzerland)

^e AMGEN LTD   (United Kingdom)

^f ASTRAZENECA   (United Kingdom)

^g IQVIA   (United States)

^h EISAI CO LTD   (Japan)

ⁱ GLAXOSMITHKLINE   (United Kingdom)

^j Independent Consultant   (United Kingdom)

^k Livedata (UK) Ltd   (United Kingdom)

^l LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^m KING'S COLLEGE LONDON   (United Kingdom)

more..

Author keywords

estimands; ICH E9; sensitivity analyses

Indexed keywords

ARTICLE; CLINICAL DECISION MAKING; CLINICAL DEVELOPMENT PLAN; DOCUMENTATION; DRUG DEVELOPMENT; EDUCATION; ESTIMAND; INTERPERSONAL COMMUNICATION; MEDICAL SOCIETY; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL CONCEPTS; STUDY DESIGN; CLINICAL TRIAL (TOPIC); DRUG DESIGN; DRUG INDUSTRY; HUMAN; METHODOLOGY; PROCEDURES; STATISTICAL MODEL;

CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DRUG DESIGN; DRUG INDUSTRY; HUMANS; MODELS, STATISTICAL; RESEARCH DESIGN;

EID: 84962559430     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.1745     Document Type: Article

References (10)

1. ICH E9 Expert Working Group. Statistical Principles for Clinical Trials: ICH Harmonized Tripartite Guideline. Statistics in Medicine 1999; 18: 1905–1942.
2. Garrett A. Choosing Appropriate Estimands in Clinical Trials (Leuchs et al): Letter to the Editor. Therapeutic Innovation and Regulatory Science 2015; 49(4): 601.
3. Available at: https://en.wiktionary.org/wiki/estimand (Accessed February 2016).
4. Available at: https://en.wikipedia.org/wiki/Estimand (accessed 29.02.2016).
5. Akacha M. Estimands and their role in clinical trials. Talk given at the Joint DIA/AEMPS Statistics Workshop on Statistical methodology in Clinical R&D, barcelona, Spain, 2014.
6. Akacha M, Bretz F, Ohlssen D, Rosenkranz G, Schmidli H. Estimands and their role in clinical trials. Summer issue of the American Statistical Association's Biopharmaceutical Section Report, vol. 22, 2015; 1–4.
7. Leuchs A, Zinserling J, Brandt A, Wirtz D, Benda N. Choosing appropriate estimands in clinical trials. Therapeutic Innovation and Regulatory Science, 2015. Available at: http://dij.sagepub.com/content/early/2015/02/13/2168479014567317 (Accessed February 2016).
8. Mallinckrodt CH, Lin Q, Lipkovich I, Moldenberghs G. A structured approach to choosing estimands and estimators in longitudinal clinical trials. Pharmaceutical Statistics 2012; 11: 456–461.
9. Little R, Kang S. Intention to treat analysis with treatment discontinuation and missing data in clinical trials. Statistics in Medicine 2015; 34: 2381–2390.
10. Hughes S, Harris J, Flack N, Cuffe RL. The statistician's role in the prevention of missing data. Pharmaceutical Statistics 2012; 11: 410–416.